secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0000950170-24-022068
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics reports Q4 net loss of $60.1M; announces $350M private placement; paltusotine NDA on track for 2H 2024
--------------------------------------------------------------------------------

- Net loss for Q4 2023 was $60.1M vs $45.0M in Q4 2022; full-year net loss $214.5M vs $163.9M in 2022.
- Cash, equivalents, and investments totaled $558.6M as of Dec 31, 2023; $350M private placement extends runway into 2028.
- Phase 3 PATHFNDR-2 topline results for paltusotine in acromegaly expected March 2024; NDA submission planned 2H 2024.
- Phase 2 paltusotine in carcinoid syndrome full topline results expected 1H 2024; initial data from 27 patients reported Dec 2023.
- R&D expenses rose to $168.5M for FY2023 from $130.2M in FY2022, driven by higher personnel and outside services costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024022068/0000950170-24-022068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024022068/crnx-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-022068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer